| scholarly article | Q13442814 |
| P2093 | author name string | Aleksandar Videnovic | |
| Diego Golombek | |||
| P2860 | cites work | Nonphotic entrainment of the human circadian pacemaker | Q74518637 |
| Characteristic findings on 24-h ambulatory blood pressure monitoring in a series of patients with Parkinson's disease | Q80235684 | ||
| Orthostatic heart rate variability analysis in idiopathic Parkinson's disease | Q83184994 | ||
| Leptin, adiponectin, and resistin secretion and diurnal rhythmicity are unaltered in Parkinson's disease | Q83309328 | ||
| A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease | Q21651045 | ||
| Dopamine and retinal function | Q22251337 | ||
| Evaluation of Models of Parkinson's Disease | Q26772843 | ||
| 'The clocks that time us'--circadian rhythms in neurodegenerative disorders | Q26824646 | ||
| Genetically engineered mouse models of Parkinson's disease | Q26852964 | ||
| Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson's disease | Q27322880 | ||
| Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model | Q28384426 | ||
| Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease | Q30383888 | ||
| Mania-like behavior induced by disruption of CLOCK | Q30479252 | ||
| A new approach in the assessment of motor activity in Parkinson's disease | Q33590050 | ||
| Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa | Q72918893 | ||
| Abnormalities in blood pressure regulation in a patient with Parkinson's disease | Q73634065 | ||
| Diurnal effects of motor activity and fatigue in Parkinson's disease | Q33591568 | ||
| Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity | Q33617472 | ||
| Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa | Q33629155 | ||
| Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease | Q33835856 | ||
| Bright light therapy: side effects and benefits across the symptom spectrum. | Q33844953 | ||
| Sleep and circadian rhythm regulation in early Parkinson disease | Q33992743 | ||
| Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study | Q34108581 | ||
| Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting | Q34131330 | ||
| Bright light resets the human circadian pacemaker independent of the timing of the sleep-wake cycle | Q34188646 | ||
| Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects | Q34436566 | ||
| The development of circadian rhythms in the fetus and neonate | Q34485593 | ||
| Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study | Q34646419 | ||
| Unwinding the molecular basis of interval and circadian timing. | Q35379888 | ||
| Ambulatory ECG and analysis of heart rate variability in Parkinson's disease | Q35461193 | ||
| Circadian clock genes: effects on dopamine, reward and addiction | Q35689041 | ||
| Repeat variation in the human PER2 gene as a new genetic marker associated with cocaine addiction and brain dopamine D2 receptor availability | Q35844253 | ||
| Animal models of the non-motor features of Parkinson's disease | Q36235578 | ||
| Blood pressure disorders during Parkinson's disease: epidemiology, pathophysiology and management | Q36558675 | ||
| Circadian system - A novel diagnostic and therapeutic target in Parkinson's disease? | Q36665097 | ||
| Circadian Rhythms, Sleep, and Disorders of Aging | Q36731044 | ||
| Circadian variation in restless legs syndrome | Q36769615 | ||
| Circadian and sleep disorders in Parkinson's disease | Q36882599 | ||
| Parkinson's disease incidence: magnitude, comparability, time trends | Q36925789 | ||
| Sleep disorders in Parkinson's disease: an overview | Q37050639 | ||
| A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q37343442 | ||
| Minutes, days and years: molecular interactions among different scales of biological timing | Q37494518 | ||
| Sleep and Alzheimer disease pathology--a bidirectional relationship | Q37691522 | ||
| "Sleep benefit" in Parkinson's disease: a systematic review | Q38101462 | ||
| Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates | Q38243417 | ||
| Circadian insights into dopamine mechanisms. | Q38256657 | ||
| Dual regulation of clock gene Per2 expression in discrete brain areas by the circadian pacemaker and methamphetamine-induced oscillator in rats | Q38309667 | ||
| Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial | Q38389742 | ||
| Modeling sleep alterations in Parkinson's disease: How close are we to valid translational animal models? | Q38545082 | ||
| ??? | Q64795549 | ||
| Aging and circadian disruption: causes and effects | Q38608498 | ||
| Molecular mechanism regulating 24-hour rhythm of dopamine D3 receptor expression in mouse ventral striatum | Q39190694 | ||
| Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring | Q39396982 | ||
| Studies on the prevalence of paralysis agitans by tracer methodology. | Q39664503 | ||
| Nighttime sleep problems and daytime sleepiness in Parkinson's disease | Q40160509 | ||
| Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. | Q40273125 | ||
| Effects of light therapy on sleep, mood, and temperature in women with nonseasonal major depression | Q40393817 | ||
| Effects of bilateral striatal 6-OHDA lesions on circadian rhythms in the rat: a radiotelemetric study | Q40748367 | ||
| Neurodegeneration, sleep, and cerebral energy metabolism: a testable hypothesis | Q41429786 | ||
| Daily rhythms of serotonin metabolism and the expression of clock genes in suprachiasmatic nucleus of rotenone-induced Parkinson's disease male Wistar rat model and effect of melatonin administration | Q42703530 | ||
| Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. | Q42852553 | ||
| Diurnal worsening in Parkinson patients treated with levodopa | Q44696765 | ||
| Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light | Q44792181 | ||
| Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. | Q45295709 | ||
| Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study. | Q46006501 | ||
| Morphine withdrawal produces circadian rhythm alterations of clock genes in mesolimbic brain areas and peripheral blood mononuclear cells in rats | Q46042359 | ||
| Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations | Q46354633 | ||
| Circadian dysfunction in a mouse model of Parkinson's disease | Q46527998 | ||
| Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model | Q46545135 | ||
| Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice | Q46753371 | ||
| Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease | Q46799352 | ||
| Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease. | Q48033804 | ||
| Sleep dysfunction and EEG alterations in mice overexpressing alpha-synuclein | Q48104086 | ||
| Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. | Q48125649 | ||
| D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism. | Q48144452 | ||
| Diurnal secretion profiles of growth hormone, thyrotrophin and prolactin in Parkinson's disease | Q48308907 | ||
| Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus | Q48343381 | ||
| Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson's disease | Q48382156 | ||
| Circadian rhythms in catecholamine metabolites and cyclic nucleotide production | Q48422819 | ||
| The frequency and nature of sleep disorders in a community-based population of patients with Parkinson's disease | Q48450083 | ||
| Circadian heart rate variability in Parkinson's disease | Q48452134 | ||
| The vasopressin and oxytocin neurons in the human supraoptic and paraventricular nucleus; changes with aging and in senile dementia | Q48453913 | ||
| Bright light therapy in Parkinson's disease: a pilot study | Q48468410 | ||
| Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs | Q48480245 | ||
| Nocturnal cardiac autonomic regulation in Parkinson's disease | Q48595585 | ||
| 'Sleep benefit' in Parkinson's disease | Q48800035 | ||
| A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease | Q48800057 | ||
| Assessment of response fluctuations in Parkinson's disease by ambulatory wrist activity monitoring | Q48873645 | ||
| Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease | Q48878240 | ||
| A novel effect of MPTP: the selective suppression of paradoxical sleep in cats | Q48916712 | ||
| Circadian variation of core body temperature in Parkinson disease patients with depression: a potential biological marker for depression in Parkinson disease. | Q51892920 | ||
| Circadian modulation of interval timing in mice. | Q51895664 | ||
| Circadian fluctuations of contrast sensitivity in Parkinson's disease. | Q52492637 | ||
| Global depletion of dopamine using intracerebroventricular 6-hydroxydopamine injection disrupts normal circadian wheel-running patterns and PERIOD2 expression in the rat forebrain. | Q52609942 | ||
| Involvement of dopamine signaling in the circadian modulation of interval timing. | Q52649021 | ||
| Heart rate variability and Parkinson?s disease severity | Q57667199 | ||
| Heart rate variability in patients with untreated Parkinson's disease | Q64764275 | ||
| Twenty-four-hour heart rate variability to assess autonomic function in Parkinson's disease | Q64863089 | ||
| Epidemiology of Parkinson's disease | Q64944300 | ||
| Sleep benefit in Parkinson's disease. | Q67207561 | ||
| Circadian secretion pattern of melatonin in Parkinson's disease | Q70219636 | ||
| P921 | main subject | circadian rhythm | Q208353 |
| P304 | page(s) | 53-58 | |
| P577 | publication date | 2016-11-12 | |
| P1433 | published in | Neurobiology of sleep and circadian rhythms | Q27727617 |
| P1476 | title | Circadian Dysregulation in Parkinson's Disease | |
| P478 | volume | 2 |
| Q60912710 | Circadian Rhythm Abnormalities in Parkinson's Disease from Humans to Flies and Back |
| Q64868188 | Impaired Photic Entrainment of Spontaneous Locomotor Activity in Mice Overexpressing Human Mutant α-Synuclein. |
| Q64762188 | Parkin Mutation Affects Clock Gene-Dependent Energy Metabolism |
| Q64816403 | Rhythms of life: circadian disruption and brain disorders across the lifespan |
| Q60956179 | overexpression disturbs hippocampal gene expression trajectories in midlife |
Search more.